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Purpose or Objective: To investigate the association 
between external beam radiotherapy (EBRT) and pleural and 
peritoneal mesothelioma among long-term (>5 years) solid 
cancer survivors. 
 
Material and Methods: We analysed data from the US 
Surveillance, Epidemiology, and End Results (SEER) program 
(1973-2012). We fitted survival models adjusted by age, 
gender, race, year, surgery, and relative risk of primary 
mesothelioma in the county of residence (proxy for individual 
asbestos exposure). We estimated hazard ratios [HR] with 
reference to non-irradiated patients. We distinguished 
between scattered and direct irradiation to study the dose-
response. 
 
Results: We observed 300 mesotheliomas (264 pleural; 32 
peritoneal; 4 others) among 913,873 patients. EBRT increased 
the risk of mesothelioma (any site; HR 1.36, 95%CI 1.05–
1.76). We observed an increased risk of pleural mesothelioma 
(HR for EBRT 1.35, 95%CI 1.02–1.78), but we did not find signs 
of a dose-response relationship (HR for scattered irradiation 
1.35; HR for direct irradiation 1.36). On the opposite, only 
direct peritoneal irradiation was associated with peritoneal 
mesothelioma (HR 2.13, 95%CI 0.96–4.74), particularly for 
latencies ≥10 years (HR 3.19, 95%CI 1.11–9.18). A competing 
risks analysis revealed that the clinical impact of radiation-
induced mesothelioma was limited by the high frequency of 
competing events. The cumulative incidence function of 
mesothelioma after 40 years of observation was very low 
(non-irradiated patients: 0.00031, irradiated patients: 
0.00056). 
 
Conclusion: EBRT is a determinant of mesothelioma. Longer 
latency periods are associated with higher risks, while the 
dose-response seems non-linear. The clinical impact of 
mesothelioma after EBRT for primary solid cancers is very 
limited.  
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Purpose or Objective: To evaluate the clinical efficacy and 
toxicity of stereotactic body radiotherapy (SBRT) with 
respiratory motion management in patients with 
oligometastatic cancer. 
 
Material and Methods: Patients with five or less metastases 
were eligible for this prospective trial. A four-dimensional 
respiration-correlated CT (4D-CT) was obtained for planning. 
In metastases with significant motion, a fiducial marker was 
implanted for dynamic tracking using the gimbaled Vero SBRT 
system, otherwise an internal target volume (ITV) was 
defined to encompass the tumor trajectory. ITV-targets were 
also treated on Vero, unless numbering 4 or more, in which 
case tomotherapy was used. A dose of 50 Gy in 10 fractions 
of 5 Gy was prescribed on the 80% isodose line, covering the 
planning target volume.  
 
Results: We treated 87 metastases in 44 patients, with 
colorectal cancer as the most common primary origin 
(65.9%). Metastatic sites were mainly lung (n=62) and liver 
(n=17). Twenty-seven metastases, of which 12 in lung, 14 in 
liver and 1 in a kidney, were treated with dynamic tracking, 
the remaining 60 using the ITV-concept. Three patients (7%) 
experienced grade ≥3 toxicity, of which one with a liver 
metastasis invading the major bile ducts with grade 5 
cholangitis due to bile duct stenosis. After a median follow-
up of 12 months. we report an actuarial one-year local 
control (LC) of 89% for the whole group (95% CI 77–95%), with 
corresponding values of 90% and 88% for the metastases 
irradiated with the ITV-approach and dynamic tracking, 
respectively. Median progression-free survival reached 6.5 
months, one-year overall survival 97%. 
 
Conclusion: This first clinical trial on Vero dynamic tracking 
shows favorable efficacy. SBRT with respiratory motion 
management resulted in a high LC and acceptable toxicity 
profile in oligometastatic cancer patients.  
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Purpose or Objective: Contrast enhanced radiotherapy 
(CERT) has already been shown to be a promising antitumor 
modality capable to overcome some limitation inherent to 
conventional beam radiotherapy. Depth dose distribution in 
CERT is characterized by local dose increase in a volume, 
which incorporates certain amount of a high atomic number 
element. Photoabsorption of external X-ray radiation by high 
atomic number elements (such as iodine, gadolinium, gold 
etc.) leads to absorbed dose enhancement exactly in the 
region of the element location. Dose increase is caused by 
emission of short range secondary radiation such as 
characteristic X-rays, photoelectrons and Auger electrons. 
Dose enhancement in CERT for particular high atomic number 
element is strongly dependent on energy spectrum of 
external radiation. Calculations of many researchers show 
that significant part of absorbed dose is caused by Auger-
electrons especially in the close vicinity (about 1 um) of 
emitting atom. Because of their extremely short range in 
water Auger-electrons are not detectable by most dosimetric 
tools such as ionizing chambers, radiochromic films etc. 
However ferrosulfate based dosimeters (Fricke dosimeters) 
can be used to measure total absorbed dose caused by 
photoabsorption of external X-ray radiation by high atomic 
number elements. 
 
Material and Methods: Direct dose enhancement was 
measured for iodine in the chemical form of iopromide 
(Ultravist 370, Bayer) and gadolinium in the from of 
gadolinium sulfate (Sigma-Aldrich). Fricke dosimeter solution 
was prepared by standard procedure described elsewhere. 
ESTRO 35  2016                                                                                                                                                  S373 
________________________________________________________________________________ 
Iopromide and gadolinium sulfate solutions were introduced 
into standard Fricke dosimeter solution for final 
concentrations of iodine from 2.5 mg I/ml to 50 mg I/ml and 
gadolinium from 5 mg Gd/ml to 10 mg Gd/ml. Detection of 
iron (III) ions was performed with spectrophotometer Varian 
Cary 50. For measurement of iron (III) ions concentration in 
the presence of iopromide ammonium tiocianate (Panreac) 
was used as an indicator because optical spectrum of 
iopromide interfere with optical spectrum of iron (III) ions. 
Irradiation of Fricke solutions was performed with 110 kVp X-
rays through 3.5 mm Al filter at 0.7 Gy/min dose rate. 
 
Results: Dose enhancement in presence of iodine and 
gadolinium was expressed as dose enhancement factor (DEF), 
which is the ratio of absorbed dose value in Fricke water 
solution containing iodine or gadolinium and in pure Fricke 
water solution. Measured DEF values and corresponded iodine 
and gadolinium concentrations are presented in Table. 
 
  
Dose enhancement is proportional to concentration of the 
element used. DEF value for iodine varies from 1.2±0.1 to 
4.8±0.5 for concentration of iodine from 2.5 mg I/ml to 50 
mg I/ml respectively. 
 
Conclusion: A new approach for measuring dose 
enhancement in CERT was proposed. This method can be 
used as a routing procedure in experimental and clinical 
practice of CERT dose measurements.  
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Purpose or Objective: The Advanced Markus ionization 
chamber from PTW (PTW-Freiburg GmbH, Freiburg, Germany) 
saturates at high dose rates (Ḋ) and/or at a high dose-per-
pulse (DPP). According to PTW, the ion collection efficiency 
is ≥ 99% at continuous Ḋ < 375 Gy/s and at DPP < 5.56 mGy. 
At a source-to-surface distance (SSD) of 50 cm, our prototype 
linac produces a mean Ḋ of ≈ 500 Gy/s, an instantaneous Ḋ of 
≈ 2.5 MGy/s, and a DPP of ≈ 5 Gy (far above the chamber 
datasheet range). In order to use the Advanced Markus 
chamber for determining the absorbed dose in these intense 
radiation conditions, we needed to establish a model of its 
saturation as the Ḋ/DPP increases. 
 
Material and Methods: Two independent methods were used 
to determine the chamber saturation curve. 1) Measurements 
in a water phantom at different Ḋ/DPP by varying the SSD 
and the linac gun grid tension (pulse amplitude). The 
hypothesis was that if the linac output varies with grid 
tension in a reproducible way and if the grid tension was 
varied by the same factor for every SSD then the relative 
change in chamber response with grid tension should be the 
same for all SSD if not for the chamber saturation. 2) 
Simultaneous measurements of chamber and Ḋ/DPP 
independent radiochromic film (Gafchromic™ EBT3, Ashland 
Inc., Covington, USA), in a solid water phantom (RW3 slabs, 
PTW) at various Ḋ/DPP.  
 
Results: The results show how the chamber saturation 
increases (the ion collection efficiency decreases) as the DPP 
increases (Figure). These results also show that the chamber 
saturation is much more dependent on the DPP than the 
instantaneous Ḋ, as the ion collection efficiency curves for 
the different pulse widths (= DPP/instantaneous Ḋ) are only 
slightly separated when plotted against DPP.  
A mathematical model of the saturation curves was 
established by fitting a logistic function (dependent on DPP) 
to the data points: 
 
 
Where ks is the saturation (ion recombination) correction 
factor and where a takes a slightly different value for 
different instantaneous Ḋ (a = 0.197, 0.192, and 0.184 for 
pulse widths of 0.5, 1.0, and 1.8 μs, respectively).  
 
 
 
Results from subsequent dose measurements at various 
Ḋ/DPP verified that chamber dose values (corrected by the 
saturation model) were compatible with film and TLD dose 
values. 
 
Conclusion: We present a saturation model for the Advanced 
Markus ionization chamber, which was based on dose 
measurements performed in a water phantom as well as 
simultaneous film and chamber measurements in a solid 
water phantom, at various Ḋ/DPP. Chamber dose 
measurements corrected by the saturation model were 
compared to independent film and TLD dose measurements. 
These measurements verified that the Advanced Markus 
ionization chamber does not completely saturate up to DPP 
values of 10 Gy and can consequently be used for accurate 
dose measurements (within 5%) in ultra high Ḋ/DPP 
irradiation conditions, if the chamber saturation model is 
applied. 
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